MoonLake Immunotherapeutics Class A MLTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $19.93
- Day Range
- $19.70–21.28
- 52-Week Range
- $5.95–62.75
- Bid/Ask
- $19.80 / $20.95
- Shares Outstanding
- 83.56M
- Market Cap
- $1.70B
- Volume/Avg
- 2M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 130
- Website
- https://www.moonlaketx.com
Valuation
|
Metric
|
MLTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.44 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MLTX
|
|---|---|
Quick Ratio | 7.89 |
Current Ratio | 8.60 |
Interest Coverage | −26.20 |
Quick Ratio
MLTX
Profitability
|
Metric
|
MLTX
|
|---|---|
Return on Assets (Normalized) | −53.27% |
Return on Equity (Normalized) | −73.20% |
Return on Invested Capital (Normalized) | −55.84% |
Return on Assets
MLTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?Wr?dl | LOCK|>S&< | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|rL%$%nK | LOCK|y&tN | $70B | |||
| argenx SE ADR
ARGX
| LOCK|HJnXhr | LOCK|py# | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|n%?qRl | LOCK|^LR> | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Znt#VZ | LOCK|!^D | $36B | |||
| Moderna Inc
MRNA
| LOCK|Hff@#& | LOCK|Kn | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|XVhX!J%@ | LOCK|z#$<G | $25B | |||
| Incyte Corp
INCY
| LOCK|^fW?!< | LOCK|<&? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|sG<!s# | LOCK|jn | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|D^spHc | LOCK|^!@ | $17B |
United States